Ardelyx Drug Patent Portfolio
Ardelyx owns 2 orange book drugs protected by 8 US patents Given below is the list of Ardelyx's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12539299 | 26 Nov, 2042 | Active | |
| US10272079 | NHE3-binding compounds and methods for inhibiting phosphate transport | 10 Apr, 2034 | Active |
| US10940146 | NHE3-binding compounds and methods for inhibiting phosphate transport | 10 Apr, 2034 | Active |
| US8541448 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | 01 Aug, 2033 | Active |
| US9006281 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | 02 May, 2030 | Active |
| US12016856 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | 30 Dec, 2029 | Active |
| US8969377 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | 30 Dec, 2029 | Active |
| US9408840 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder | 30 Dec, 2029 | Active |
Latest Legal Activities on Ardelyx's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Ardelyx.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Mail Examiner Interview Summary (PTOL - 413) | 10 Nov, 2025 | US12539299 |
| Mail Examiner Interview Summary (PTOL - 413) | 10 Nov, 2025 | US12539299 |
| Email Notification | 10 Nov, 2025 | US12539299 |
| Email Notification | 10 Nov, 2025 | US12539299 |
| Date Forwarded to Examiner | 06 Nov, 2025 | US12539299 |
| Interview Summary Record | 06 Nov, 2025 | US12539299 |
| Interview Summary - Applicant Initiated - Telephonic | 06 Nov, 2025 | US12539299 |
| Interview Summary Record | 06 Nov, 2025 | US12539299 |
| Date Forwarded to Examiner | 06 Nov, 2025 | US12539299 |
| Interview Summary - Applicant Initiated - Telephonic | 06 Nov, 2025 | US12539299 |
| Response after Non-Final Action | 23 Oct, 2025 | US12539299 |
| Response after Non-Final Action | 23 Oct, 2025 | US12539299 |
| Mail Non-Final Rejection | 15 Sep, 2025 | US12539299 |
| Mail Non-Final Rejection | 15 Sep, 2025 | US12539299 |
| Electronic Review | 15 Sep, 2025 | US12539299 |
Ardelyx's Family Patents
Ardelyx drugs have patent protection in a total of 21 countries. It's US patent count contributes only to 31.1% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Ardelyx Drug List
Given below is the complete list of Ardelyx's drugs and the patents protecting them.
1. Ibsrela
Ibsrela is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12539299 |
26 Nov, 2042
(16 years from now)
| Active | |
| US8541448 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
01 Aug, 2033
(7 years from now)
| Active |
| US9006281 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
02 May, 2030
(3 years from now)
| Active |
| US12016856 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
30 Dec, 2029
(3 years from now)
| Active |
| US8969377 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
30 Dec, 2029
(3 years from now)
| Active |
| US9408840 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorder |
30 Dec, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ibsrela's drug page
2. Xphozah
Xphozah is protected by 6 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12539299 |
26 Nov, 2042
(16 years from now)
| Active | |
| US10272079 | NHE3-binding compounds and methods for inhibiting phosphate transport |
10 Apr, 2034
(7 years from now)
| Active |
| US10940146 | NHE3-binding compounds and methods for inhibiting phosphate transport |
10 Apr, 2034
(7 years from now)
| Active |
| US8541448 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
01 Aug, 2033
(7 years from now)
| Active |
| US12016856 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
30 Dec, 2029
(3 years from now)
| Active |
| US8969377 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
30 Dec, 2029
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Xphozah's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List